Electra Therapeutics (NASDAQ:ETRA) Stock: Insider Carl Gordon Buys 20,000 Shares

Electra Therapeutics, Inc. (NASDAQ:ETRA – Get Free Report) Director Carl Gordon bought 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 9th. The shares were acquired at an average cost of $8.24 per share, for a total transaction of $164,800.00. Following the purchase, the director directly owned 5,234,578 shares in the company, valued at $43,132,922.72. This trade represents a 0.38% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Electra Therapeutics Stock Performance

Shares of ETRA opened at $9.45 on Thursday. Electra Therapeutics, Inc. has a 12-month low of $6.86 and a 12-month high of $15.50.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Evercore started coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 target price on the stock. Zacks Research upgraded shares of Electra Therapeutics to a “hold” rating in a research report on Wednesday, October 14th. JPMorgan Chase & Co. began coverage on shares of Electra Therapeutics in a research note on Thursday, October 22nd. They set an “overweight” rating and a $36.00 target price for the company. TD Cowen began coverage on shares of Electra Therapeutics in a report on Tuesday, October 13th. They issued a “buy” rating on the stock. Finally, HC Wainwright assumed coverage on shares of Electra Therapeutics in a report on Monday, October 26th. They issued a “buy” rating and a $30.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, Electra Therapeutics presently has an average rating of “Buy” and an average target price of $33.50.

View Our Latest Stock Analysis on ETRA

Trending Headlines about Electra Therapeutics

Investors following ETRA have been watching these headlines:

  • Positive Sentiment: OrbiMed reported buying 92,116 shares on November 6, 9 and 10 for about $744,500 in total, adding to purchases earlier in November. Repeated insider buying may support investor confidence, though it does not guarantee future performance. Insider purchase report
  • Neutral Sentiment: A short-interest update reported zero shares short and zero days to cover as of November 10, but also described short interest as having increased, an apparent inconsistency that makes the data difficult to interpret.

Electra Therapeutics Company Profile

(Get Free Report)

Electra Therapeutics, Inc. (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function. Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.

Recommended Stories

Insider Buying and Selling by Quarter for Electra Therapeutics (NASDAQ:ETRA)

Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.